Leprosy (Hansen disease)
Leprosy · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Leprosy is chronic infection by Mycobacterium leprae/lepromatosis affecting skin and peripheral nerves, classified across a spectrum from paucibacillary to multibacillary. Multidrug therapy cures infection; immune reactions can cause acute nerve damage.
Red flags
- Acute nerve pain/tenderness or new weakness (reaction - emergency for nerves)
- Loss of sensation threatening hands/feet/eyes
- Severe erythema nodosum leprosum with systemic illness
- Eye involvement risking blindness
- Rapidly progressive neuritis
Assessment
Differential diagnosis
- Other causes of peripheral neuropathy
- Fungal/other granulomatous skin disease
- Cutaneous leishmaniasis
- Sarcoidosis
- Vitiligo / other hypopigmented dermatoses
Investigations
- Slit-skin smears for acid-fast bacilli (bacillary index)
- Skin and/or nerve biopsy with histology
- Assessment of peripheral nerve thickening and sensory/motor function
- Classification (number of lesions, smear positivity)
- Baseline G6PD before dapsone
- Monitoring of nerve function over time
Management
- Diagnose via characteristic anaesthetic skin lesions and/or thickened nerves with AFB
- Classify as paucibacillary or multibacillary (lesion count and smears)
- Check G6PD status before dapsone
- Start WHO multidrug therapy appropriate to classification
- Educate on long treatment, adherence and the need to report reactions
- Assess and protect anaesthetic hands/feet/eyes (disability prevention)
- Recognise and treat leprosy reactions (type 1 reversal, type 2 ENL) urgently to save nerves
- Use corticosteroids for neuritis/reactions; thalidomide for severe ENL where available
- Provide physiotherapy and footwear/eye care to prevent deformity
- Screen household contacts and consider single-dose rifampicin prophylaxis
- Monitor for drug toxicity and clinical response
- Arrange long-term rehabilitation and follow-up
Drugs & doses
Multibacillary: rifampicin 600 mg monthly + dapsone 100 mg daily + clofazimine 300 mg monthly/50 mg daily for 12 months
Paucibacillary: rifampicin 600 mg monthly + dapsone 100 mg daily (+ clofazimine) for 6 months
Prednisolone 40-60 mg PO daily tapering for type 1 reactions/neuritis
Thalidomide 100-300 mg PO daily for severe type 2 (ENL) reactions (not in pregnancy)
Single-dose rifampicin 600 mg for eligible contacts (post-exposure prophylaxis)
Disposition
Outpatient leprosy/dermatology service; admit for severe reactions; long-term rehabilitation.
Complications & pitfalls
- Permanent nerve damage and deformity
- Trophic ulcers and secondary infection
- Blindness
- Leprosy reactions (type 1 and type 2/ENL)
- Dapsone haemolysis/hypersensitivity
Exam pearls
- Reactions are the main cause of nerve damage - treat promptly with corticosteroids
- WHO multidrug therapy renders patients non-infectious quickly
- Check G6PD before dapsone to avoid severe haemolysis
- Disability prevention (self-care of anaesthetic limbs) is as important as antibiotics
- Single-dose rifampicin reduces leprosy risk in contacts
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.